Contents
Contents
Unnecessary urine drug testing physician fraud involves knowingly billing government health programs for tests ordered without an individual medical need. In pain practices, the medical-necessity problem can begin with a standing order that sends every patient through the same testing routine. The practice orders the screen and the more expensive follow-up together, without using the first result to decide whether the second test belongs. If you work with those orders, you may know exactly where the patient’s care stopped driving the process.
A presumptive urine drug screen looks for the presence or absence of drugs or drug classes. More specific testing can identify a particular drug and measure its concentration.
That distinction matters because the second order needs its own clinical reason. In its Physicians Group Services announcement, the Justice Department explained that the value of quantitative testing depends partly on whether the initial result was expected, the patient’s medication adherence and drug-use history, clinical presentation and medical history. The office appointment, the screen and the outside laboratory’s work may all arise from the same visit, but the records need to show who ordered each service, who performed it and who billed the government.
A standing testing policy can put the order ahead of the clinical decision. The whistleblower’s complaint against Comprehensive Pain Specialists alleged that medical assistants ordered repetitive panels for up to 17 drugs before professionally trained staff could assess whether the patient needed testing. Its description of the electronic workflow makes the allegation concrete: a training-manual template called for both qualitative and quantitative screens, and staff selected panels within the practice’s medical-record system.
The complaint alleged that established patients faced testing at least every two months regardless of individual need. According to the whistleblower, selecting the panel sent both orders to the practice’s laboratories at the same time. A frequency rule in the office manual had become a patient order before the clinician made a patient decision.
The whistleblower’s complaint against National Spine and Pain Centers described another route to the same result. After an in-office twelve-panel screen, a medical assistant allegedly sent the same sample to an outside laboratory for the same drug classes plus nicotine. The complaint alleged retesting even for drugs the patient had not reported taking and that the office screen had already found negative.
National Spine and Pain Centers and Physical Medicine Associates agreed to pay approximately $3.3 million in April 2019 to resolve allegations that included unnecessary urine tests, improper testing referrals and billing nonphysician services as physician services. A former physician assistant brought the whistleblower case. The complaint’s account shows why the test menu, the staff instructions and the destination laboratory matter alongside the physician’s signature.
Result review connects a test to the care it was supposed to guide. The Comprehensive Pain Specialists complaint alleged that results were available in the electronic record within five to seven days, yet staff sometimes reviewed them months later or never used them in medical management. Meanwhile, the next round of full testing continued.
One Medicare patient allegedly received six screens within ten months without a noncompliant result. The whistleblower said staff took 139 days to review one of those results. We find the contradiction hard to miss: an office insists on repeated monitoring while leaving the information that supposedly justifies the monitoring unread.
Another patient allegedly had repeated positive results without a documented response in the treatment record. The complaint tied that failure directly to the government bills:
Claims for all of these urine drug screens were submitted to Medicare even though the results were ignored by CPS staff and not used in the patient’s medical management or care.
The useful comparison runs from the result’s availability to the clinician’s review and the next treatment decision. The complaint described a chart that marked a result compliant despite positive findings, followed by more tests without documented use of their results. An insider familiar with the result inbox and progress notes can explain that gap in a way the billing total cannot.
In April 2021, Comprehensive Pain Specialists, its majority owners and a former executive agreed to a $4.1 million civil resolution. The allegations included medically unnecessary or non-reimbursable urine drug, specimen-validity, genetic and psychological testing, along with other services.
The financial arrangement can explain why the same order keeps appearing. Physician Partners of America managed pain practices and indirectly owned Medical Tox Labs. The government alleged that Physician Partners required simultaneous urine tests without an individual assessment or review of initial results, while its toxicology laboratory billed federal health programs for the highest testing level.
The Justice Department’s April 2022 announcement alleged that Physician Partners paid physician employees 40% of the profits from presumptive testing. The government alleged that arrangement violated the Stark Law, the physician self-referral law. Physician Partners of America, its founder and its former chief medical officer agreed to pay $24.5 million to resolve allegations involving unnecessary testing, physician compensation and other conduct. The doctor’s incentive and the laboratory’s claim were different parts of the same alleged business model.
An independent laboratory creates a different payment trail. In the National Spine complaint, the whistleblower alleged that the outside laboratory billed government programs for the quantitative testing ordered by the practice. The complaint described an office competition, with prizes for testing volume:
National Spine rewards the office that administers the highest volume of drug tests each week with gift cards, cash prizes, and free meals at restaurants.
A 2020 article in the Journal of Forensic and Investigative Accounting, A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, describes how something free can serve the same commercial purpose. Its account of the Millennium Health settlement describes allegations that the laboratory supplied free point-of-care testing cups on the condition that physicians return specimens for additional costly tests. For an insider examining laboratory referral incentives, the condition attached to the cup matters as much as its price.
According to the Justice Department’s account of the criminal trial of Spectra Clinical Labs’ operator, the operator paid marketers a share of Medicare reimbursements to obtain expensive test orders. The marketers trained staff in physicians’ offices to send orders for panels the doctors had neither wanted nor authorized. The department said the operator knew the orders lacked documentation of medical necessity. Here the incentive reached into the practice through the outside laboratory’s marketing operation.
These arrangements leave different records: physician compensation terms, laboratory ownership, outside-lab invoices and instructions about where specimens must go. We connect each payment to the party that earned it and each order to the person or policy that generated it.
Specimen-validity work checks whether urine has been adulterated or tampered with. It can include pH, specific gravity and creatinine testing. That work concerns the sample itself, while drug testing supplies information about substances in the patient’s body.
A February 2018 HHS Office of Inspector General audit examined specimen-validity tests billed alongside urine drug tests during 2014 through 2016. It identified $66.3 million in improper Medicare payments to 4,480 laboratories and physician offices. The report explained that validity checks performed as part of drug testing were not separately billable Medicare services.
The same laboratory measurement can also serve a diagnostic purpose, such as evaluating a kidney or urinary condition. That makes the reason for the test essential to the billing comparison. A separately billed diagnostic code needs a diagnostic service behind it. Relabeling work done to validate a specimen does not change what the laboratory did.
The evidence connects the patient’s need, the order, the performed test, the government claim and the use of the result. In these cases, the revealing records sit in different places: the ordering template, laboratory report, billing system, progress note and compensation policy. We work with you to connect those records, from the decision to order both tests to the government payment and the clinician’s use of the result.
The National Spine complaint alleged that management tracked both in-house tests and outside-laboratory orders by office each day. That gives an insider a concrete connection between an individual order and a company-wide instruction. A daily testing report, read beside the actual charts, can show what management was asking the office to produce and whether the clinical record supported it.
Coastal Spine and Pain’s testing pattern drew government attention through claims data. In the August 2016 settlement announcement, the Justice Department said every billed qualitative screen had a corresponding quantitative test. The government alleged that Coastal performed the more expensive test regardless of the initial result, without a reason to question or confirm it.
Physicians Group Services, doing business as Coastal Spine and Pain, agreed to pay $7.4 million to resolve those allegations. The Justice Department developed the case through claims analysis, with investigative assistance from the HHS Office of Inspector General and the Defense Criminal Investigative Service. The matched claims gave investigators a specific practice to examine: an automatic second test.
In a separate October 2022 resolution, Physicians Group Services agreed to pay $700,000 to resolve allegations concerning quantitative tests billed to Florida Medicaid without individualized need. That announcement focused on the particular patient’s history, presentation and initial result.
Employees can bring the clinical and billing records into the same physician-practice whistleblower case. The Physician Partners of America resolution included cases brought by current or former employees, and the National Spine case began with a former physician assistant. Those roles explain why the internal order process can become visible outside the practice.
A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We work with insiders who can explain how the testing policy, the patient’s chart and the government claim fit together, and bring in whistleblower lawyers who know pain-practice testing and laboratory billing.
If you know why the same panels appeared in every order or why results went unread, speak to one of our Whistleblower Experts about how the tests were ordered. We work beside you to build your strongest whistleblower case from the orders, the patient records and the money, with pain-practice fraud whistleblower lawyers who understand the business. You bring the view from inside the office or laboratory, and we bring the experience to pursue it with you.